Skip to main content
. 2022 Jun 22;30(9):3066–3077. doi: 10.1016/j.ymthe.2022.06.013

Figure 1.

Figure 1

Schematic of αCD3-αEGFR-PD-1-OX40L GEMINI-Exos for targeted cancer immunotherapy

HA, hemagglutinin; PD-1, programmed death 1; OX40L, OX40 ligand; αCD3, anti-CD3; αEGFR, anti-EGFR; scFv, single-chain variable fragment; PDGFR TMD, transmembrane domain of human platelet-derived growth factor receptor; PD-L1/L2, programmed death-ligand 1/ligand 2.